![Lars Thomander](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Lars Thomander
Corporate Officer/Principal bij
University of Uppsala
Profiel
Lars Thomander is the founder of Hlt Konsult AB. He is currently an Associate Professor at the University of Uppsala.
Previously, he worked as the Chairman of CaptiGel AB, Medical Director-Nordic Region at Eli Lilly & Co., Medical Director at Abbott Scandinavia AB, Director at the Foundation for Pharmaceutical Medicine, Medical Director at AbbVie AB, Director at Double Bond Pharmaceutical International AB, and President of the Swedish Pharmaceutical Society.
Actieve functies van Lars Thomander
| Bedrijven | Functie | Begin |
|---|---|---|
University of Uppsala
 University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | - |
Eerdere bekende functies van Lars Thomander
| Bedrijven | Functie | Einde |
|---|---|---|
Abbott Scandinavia AB
 Abbott Scandinavia AB Abbott Scandinavia AB provides information on Rybelsus, the first approved oral GLP-1 receptor agonist containing semaglutide, used to treat adults with type 2 diabetes when diet and exercise alone are insufficient to control blood sugar levels. Abbott Scandinavia focuses on diabetes care and weight management, providing educational resources to patients and healthcare providers about Rybelsus’s benefits, risks, and practical considerations. The company is based in Solna, Sweden. Rybelsus works by mimicking a gut hormone to increase insulin secretion and reduce glucagon, thereby lowering blood sugar, and has also been shown to support weight loss when combined with lifestyle changes. The Swedish company ’ s content highlights the medication ’ s dosing regimen, potential side effects, precautions, and alternatives such as injectable semaglutide products. | Hoofd Techniek/Wetenschap/O&O | 01-01-2013 |
AbbVie AB
 AbbVie AB Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research and development pharmaceutical company | Hoofd Techniek/Wetenschap/O&O | 01-01-2013 |
| ELI LILLY AND COMPANY | Hoofd Techniek/Wetenschap/O&O | - |
Foundation for Pharmaceutical Medicine | Directeur/Bestuurslid | - |
Swedish Pharmaceutical Society | President | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
34
Eerstegraads connecties
9
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 9 |
|---|---|
Eli Lilly & Co.
 Eli Lilly & Co. Pharmaceuticals: MajorHealth Technology Manufactures, wholesales and markets pharmaceutical products | Health Technology |
University of Uppsala
University of Uppsala Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
CaptiGel AB
 CaptiGel AB BiotechnologyHealth Technology Provides patented technological platform | Health Technology |
Abbott Scandinavia AB
Abbott Scandinavia AB Abbott Scandinavia AB provides information on Rybelsus, the first approved oral GLP-1 receptor agonist containing semaglutide, used to treat adults with type 2 diabetes when diet and exercise alone are insufficient to control blood sugar levels. Abbott Scandinavia focuses on diabetes care and weight management, providing educational resources to patients and healthcare providers about Rybelsus’s benefits, risks, and practical considerations. The company is based in Solna, Sweden. Rybelsus works by mimicking a gut hormone to increase insulin secretion and reduce glucagon, thereby lowering blood sugar, and has also been shown to support weight loss when combined with lifestyle changes. The Swedish company ’ s content highlights the medication ’ s dosing regimen, potential side effects, precautions, and alternatives such as injectable semaglutide products. | |
Foundation for Pharmaceutical Medicine | |
Swedish Pharmaceutical Society | |
AbbVie AB
AbbVie AB Miscellaneous Commercial ServicesCommercial Services Operates as a clinical research and development pharmaceutical company | Commercial Services |
Double Bond Pharmaceutical International AB
 Double Bond Pharmaceutical International AB BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Hlt Konsult AB |
